Insulin Therapy: Types, Devices, and Practical Management

Postprandial insulin secretion and historical context

After a meal, there are postprandial peaks of insulin secretion; insulin release increases in response to circulating glucose after eating.
The lecturer references the physiologic study of glucose-driven insulin response in the blood; attribution discussions mention a researcher (historically associated with Nobel Prize work on insulin discovery) and the Nobel Prize connection to Banting and Best for insulin discovery (the transcript contains a misnaming, but the key idea is that insulin was discovered, Nobel Prize awarded, and initial work involved animal models, including dogs).
Early work on insulin involved animal models (e.g., dogs) before progression to human therapeutic use; later, insulin products were developed and marketed.
The onset of action of ultrashort/rapid-acting insulins is quick, enabling flexible timing with meals (just before, with, or just after a meal). The patient can delay insulin if there is a delay in lunch.

Insulin analogs and classifications (with practical timing)

Ultrashort-acting (rapid-acting) insulin analogs include:
- Insulin aspart
- Insulin lispro (often referred to as lispro in the transcript as a rapid-acting analog)
- Insulin glulisine
Key feature: rapid onset of action; can be used just before meals or around mealtime for flexible dosing.
The transcript notes that these analogs have rapid onset allowing pre-meal or post-meal dosing without lengthy planning.
Short-acting insulin (regular human insulin) and ultrashort acting analogs are contrasted by onset and duration, with rapid-acting analogs offering more flexible timing around meals.

Intermediate-acting insulin (NPH / isophane)

Mechanism: modifications to soluble insulin by adding zinc and protamine slow absorption from the injection site, prolonging duration.
Designation: commonly referred to as NPH or isophane insulin.
Pharmacodynamic goal: provide a flatter insulin profile that more closely resembles basal physiologic insulin secretion.
Benefit: reduces risk of nocturnal hypoglycemia compared to older intermediate-acting insulins, though risk is not zero if starting doses are high.
Practical note: these insulins are intended to provide basal coverage; exact hours are not required to memorize, but a basic understanding is expected.

Basal-bolus regimen and long-acting analogs

The basal-bolus regimen is discussed as the overarching approach to insulin therapy in many patients.
Basal insulin analogs (long-acting) provide steady background insulin; examples (implied by the discussion) include analogs designed to mimic natural basal secretion.
The concept of a programmable basal component is introduced via insulin pumps (see below).

Mixed insulin preparations

Mixed insulin preparations combine a short-acting insulin with an intermediate-acting insulin to reduce the number of injections.
These mixtures are not first-line in many guidelines but can be used to lower injection burden in some patients.
The lecture notes that there are multiple brands and formulations, but the specific names are not enumerated at this stage.

Initiating insulin therapy and adjusting regimens

When starting insulin, the patient will typically require insulin initially; after glycemic control is achieved, therapy can be simplified or adjusted toward basal or basal-bolus regimens.
Early management focuses on controlling initial hyperglycemia; then consideration of long-term regimen (basal-bolus) and potential transition to simpler regimens as control improves.

In-hospital insulin management for emergencies

In acute hospital settings, patients presenting with diabetic emergencies such as diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) require intravenous insulin infusions.
For milder cases or specific clinical situations, some patients may not require routine insulin, or may require reduced morning doses; decisions are patient-specific.

Insulin pump therapy (continuous subcutaneous insulin infusion, CSII)

Insulin pumps provide continuous subcutaneous insulin infusion with programmable basal rates and bolus doses.
Pumps are portable and can be connected to smartphones in modern systems; many models include CGM integration for closed-loop possibilities.
Pump options include tubed devices and newer patch pumps that do not require tubbing, with a small patch worn on the body (arm or leg).
Features include the ability to program multiple basal rates, bolus dosing for meals, and adjustments for activity or skipped meals.
In type 1 diabetes, pumps are commonly used; in type 2 diabetes, pump use is far less common.
Pumps enable precise dosing, better flexibility around meals, and the ability to adjust doses based on activity or missed meals.

Continuous glucose monitoring (CGM) and artificial pancreas concepts

When pumps are integrated with CGM, doses can be more closely matched to actual glucose levels and trends, improving glycemic control.
The combination of continuous insulin delivery with CGM provides potential for tighter control and improved quality of life by reducing injections and enabling more responsive therapy.
New technology enables even patch pumps without tubing and smartphone connectivity, facilitating ease of use and monitoring.

Advantages of continuous insulin pump therapy

Glycemic control tends to better reflect physiological secretion by allowing precise basal and bolus delivery.
Reduced risk of hypoglycemia due to programmable dosing and potential CGM integration (alerts and trend data).
Flexibility for meals and activity; ability to adjust bolus doses for each meal and to reduce or skip boluses when meals are skipped.
Improved quality of life: fewer injections per day and easier management; many patients report better adherence and convenience.
Convenience and safety features include alerts for out-of-range glucose, low insulin delivery issues, or pump dislodgement.

Disadvantages and challenges of pump therapy

Hypoglycemia risk is not eliminated; it can still occur and requires ongoing education on detection and management.
Device-related risks: mechanical failures, infusion-site infections, tubing issues (for tubed pumps), and device maintenance requirements.
Allergic reactions or insulin resistance can occur in rare cases.
Cost considerations: higher upfront and ongoing costs, with implications for healthcare systems and patient out-of-pocket expenses; the transcript mentions coverage concepts such as Medicare caps on patient out-of-pocket costs.
The need for carbohydrate counting and active management: basal-bolus regimens require ongoing calculation and adjustment, which can be challenging for some patients.
Not all patients prefer injections; pump therapy represents a lifestyle change and may require adaptation to new technology and routines.

Hypoglycemia: recognition, risks, and management

Hypoglycemia is a key risk with insulin therapy; symptoms can include sweating, palpitations, hunger, agitation, and behavioral changes.
If hypoglycemia worsens, it can progress to seizures or loss of consciousness; prompt recognition and treatment are essential.
Early symptoms result from sympathetic activation; however, concomitant beta-blocker therapy can blunt or mask these early symptoms, making hypoglycemia harder to detect.
Practical points from the lecture include advising patients on what to take, what to eat, and how to correct hypoglycemia; these are core aspects of patient education.
The concept of a therapeutic index being low highlights variability between individuals and even within the same individual over time; insulin requirements are not constant.

Variability, dosing challenges, and patient education

Insulin requirements vary between individuals; a similar hyperglycemic state and HbA1c value can still correspond to different insulin responses among individuals.
The same patient can have different responses over time, necessitating ongoing titration and monitoring.
Carbohydrate counting and dose calculation are essential components of advancing from fixed regimens to basal-bolus regimens.
Some patients dislike injections or find multiple daily injections burdensome; pumps offer an alternative but require adaptation and training.

Practical considerations, settings, and population notes

There are different clinical settings for insulin therapy (outpatient management, inpatient hospitalization, obstetric/pediatric/other specialty populations).
In type 1 diabetes, pumps are commonly used and offer significant advantages; in type 2 diabetes, pumps are less commonly required but may be used in certain cases.
For obstetric patients and pediatrics, therapy must be tailored to physiological changes and growth, with careful monitoring and dose adjustments.
The lecture emphasizes that there are many available insulin products and delivery methods, and the choice often depends on patient preference, lifestyle, cost, and clinical goals.

Take-home practical implications

Early goals: control hyperglycemia and stabilize the patient; then tailor the regimen toward a basal-bolus approach or pump-based therapy as appropriate.
When choosing insulin types, consider onset and duration, timing relative to meals, flexibility, and risk of hypoglycemia.
In emergencies (DKA/HHS), IV insulin regimens are standard in hospital settings.
Technology-enabled insulin delivery (pumps + CGM) can improve control and quality of life but requires training, monitoring, and consideration of cost and device management.
Ongoing patient education should cover hypoglycemia recognition and correction, meal planning, carbohydrate counting, and recognizing device-related issues.

Key equations or concepts present in the content (documented ideas, not explicit numerical formulas)

The concept of basal insulin providing a steady background level to mimic physiologic basal secretion.
The concept of bolus insulin dosing to cover meals and account for activity or missed meals.
The integration of CGM with insulin delivery to adjust dosing in response to glucose trends.